Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro

References

• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Flanagan KL, Best E, Crawford NW, et al. Progress and pitfalls in the quest for effective SARS-CoV-2 (COVID-19) vaccines. Front Immunol. 2020;11:579250.
   PubMed Web of Science ®Google Scholar
• Yao H, Song Y, Chen Y, et al. Molecular architecture of the SARS-CoV-2 virus. Cell. 2020 Oct 29;183(3):730–738.e13.
   PubMed Web of Science ®Google Scholar
• Beeraka NM, Sadhu SP, Madhunapantula SV, et al. Strategies for targeting SARS CoV-2: small molecule inhibitors – the current status. Front Immunol. 2020;11:552925.
   PubMed Web of Science ®Google Scholar
• Fernandes JD, Hinrichs AS, Clawson H, et al. The UCSC SARS-CoV-2 genome browser. Nat Genet. 2020 Oct;52(10):991–998.
   PubMed Web of Science ®Google Scholar
• V'Kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021 Mar;19(3):155–170.
   PubMed Web of Science ®Google Scholar
• Lin Y, Wu C, Wang X, et al. Glucosamine promotes hepatitis B virus replication through its dual effects in suppressing autophagic degradation and inhibiting MTORC1 signaling. Autophagy. 2020 Mar;16(3):548–561.
   PubMed Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, et al. Author correction: A new coronavirus associated with human respiratory disease in China. Nature. 2020 Apr;580(7803):E7.
   PubMed Web of Science ®Google Scholar
• Burkard C, Verheije MH, Wicht O, et al. Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog. 2014 Nov;10(11):e1004502.
   PubMed Web of Science ®Google Scholar
• Burkard C, Verheije MH, Haagmans BL, et al. ATP1A1-mediated src signaling inhibits coronavirus entry into host cells. J Virol. 2015 Apr;89(8):4434–4448.
   PubMed Web of Science ®Google Scholar
• Heald-Sargent T, Gallagher T. Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses. 2012 Apr;4(4):557–580.
   PubMed Web of Science ®Google Scholar
• Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015 Apr 16;202:120–134.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Pohlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 Is essential for infection of human lung cells. Mol Cell. 2020 May 21;78(4):779–784.e5.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Lu K, Mao B, et al. The interplay between emerging human coronavirus infections and autophagy. Emerg Microbes Infect. 2021 Dec;10(1):196–205.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun H, Pei R, et al. The SARS-CoV-2 protein ORF3a inhibits fusion of autophagosomes with lysosomes. Cell Discov. 2021 May 4;7(1):31.
   PubMed Web of Science ®Google Scholar
• Kao JC, HuangFu WC, Tsai TT, et al. The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR. PLoS Negl Trop Dis. 2018 Aug;12(8):e0006715.
   PubMed Web of Science ®Google Scholar
• Varghese FS, Rausalu K, Hakanen M, et al. Obatoclax inhibits alphavirus membrane fusion by neutralizing the acidic environment of endocytic compartments. Antimicrob Agents Chemother. 2017 Mar;61(3):e02227-16.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Mosbauer K, Hofmann-Winkler H, et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature. 2020 Sep;585(7826):588–590.
   PubMed Web of Science ®Google Scholar
• Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Yang N, Shen HM. Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19. Int J Biol Sci. 2020;16(10):1724–1731.
   PubMed Web of Science ®Google Scholar
• Hu J, Gao Q, He C, et al. Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2. Genes Dis. 2020 Dec;7(4):551–557.
   PubMed Web of Science ®Google Scholar
• Scholer L, Le-Trilling VTK, Eilbrecht M, et al. A novel In-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyze neutralizing antibodies and antiviral compounds. Front Immunol. 2020;11:573526.
   PubMed Web of Science ®Google Scholar
• Tay MZ, Poh CM, Renia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020 Jun;20(6):363–374.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Tanaka N, Tanaka Y, et al. Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. J Virol. 2007 Aug;81(16):8722–8729.
   PubMed Web of Science ®Google Scholar
• Boyd-Kimball D, Gonczy K, Lewis B, et al. Classics in chemical neuroscience: chlorpromazine. ACS Chem Neurosci. 2019 Jan 16;10(1):79–88.
   PubMed Web of Science ®Google Scholar
• Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620.
   PubMed Web of Science ®Google Scholar
• Simmons G, Gosalia DN, Rennekamp AJ, et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876–11881.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell. 2020 Apr 16;181(2):271–280.e8.
   PubMed Web of Science ®Google Scholar
• Zang R, Gomez Castro MF, McCune BT, et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol. 2020 May 13;5(47):eabc3582.
   PubMed Web of Science ®Google Scholar
• Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001–7003.
   PubMed Web of Science ®Google Scholar
• Papa G, Mallery DL, Albecka A, et al. Furin cleavage of SARS-CoV-2 spike promotes but is not essential for infection and cell-cell fusion. PLoS Pathog. 2021 Jan;17(1):e1009246.
   PubMed Web of Science ®Google Scholar
• Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19512–19517.
   PubMed Web of Science ®Google Scholar
• Denisova OV, Kakkola L, Feng L, et al. Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection. J Biol Chem. 2012 Oct 12;287(42):35324–35332.
   PubMed Web of Science ®Google Scholar
• Graham MS, Sudre CH, May A, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health. 2021 May;6(5):e335–e345.
   PubMed Web of Science ®Google Scholar
• Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 COVID-19 vaccine against the B.1.351 variant. N Engl J Med. 2021 May 20;384(20):1899–1909.
   PubMed Web of Science ®Google Scholar
• Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021 Jun 19;397(10292):2331–2333.
   PubMed Web of Science ®Google Scholar
• Consortium WHOST, Pan H, Peto R, et al. Repurposed antiviral drugs for COVID-19 - interim WHO solidarity trial results. N Engl J Med. 2021 Feb 11;384(6):497–511.
   PubMed Web of Science ®Google Scholar
• Chiappori A, Williams C, Northfelt DW, et al. Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. J Thorac Oncol. 2014 Jan;9(1):121–125.
   PubMed Web of Science ®Google Scholar
• Brown JR, Tesar B, Yu L, et al. Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56(12):3336–3342.
   PubMed Web of Science ®Google Scholar
• Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol. 2012 Sep 1;30(25):3127–3135.
   PubMed Web of Science ®Google Scholar
• McCoy F, Hurwitz J, McTavish N, et al. Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell Death Dis. 2010 Dec 16;1:e108.
   PubMed Web of Science ®Google Scholar
• Ehrenkaufer G, Li P, Stebbins EE, et al. Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity. PLoS Negl Trop Dis. 2020 Mar;14(3):e0008150.
   PubMed Web of Science ®Google Scholar
• Kuivanen S, Bespalov MM, Nandania J, et al. Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular signaling, transcription and metabolism. Antiviral Res. 2017 Mar;139:117–128.
   PubMed Web of Science ®Google Scholar
• Andersen PI, Krpina K, Ianevski A, et al. Novel antiviral activities of obatoclax, emetine, niclosamide, brequinar, and homoharringtonine. Viruses. 2019 Oct 18;11(10):964.
   PubMed Web of Science ®Google Scholar
• Ianevski A, Yao R, Fenstad MH, et al. Potential antiviral options against SARS-CoV-2 infection. Viruses. 2020 Jun 13;12(6):642.
   PubMed Web of Science ®Google Scholar
• Varghese FS, van Woudenbergh E, Overheul GJ, et al. Berberine and obatoclax inhibit SARS-Cov-2 replication in primary human nasal epithelial cells In vitro. Viruses. 2021 Feb 11;13(2):282.
   PubMed Web of Science ®Google Scholar
• Wang H, Yuan X, Sun Y, et al. Infectious bronchitis virus entry mainly depends on clathrin mediated endocytosis and requires classical endosomal/lysosomal system. Virology. 2019 Feb;528:118–136.
   PubMed Web of Science ®Google Scholar
• Li M, Khambu B, Zhang H, et al. Suppression of lysosome function induces autophagy via a feedback down-regulation of MTOR complex 1 (MTORC1) activity. J Biol Chem. 2013 Dec 13;288(50):35769–35780.
   PubMed Web of Science ®Google Scholar
• Perera RM, Di Malta C, Ballabio A. Mit/TFE family of transcription factors, lysosomes, and cancer. Annu Rev Cancer Biol. 2019 Mar;3:203–222.
   PubMedGoogle Scholar
• Settembre C, Zoncu R, Medina DL, et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 2012 Mar 7;31(5):1095–1108.
   PubMed Web of Science ®Google Scholar
• Matsuyama S, Nagata N, Shirato K, et al. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol. 2010 Dec;84(24):12658–12664.
   PubMed Web of Science ®Google Scholar
• Kawase M, Shirato K, van der Hoek L, et al. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol. 2012 Jun;86(12):6537–6545.
   PubMed Web of Science ®Google Scholar
• Shulla A, Heald-Sargent T, Subramanya G, et al. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol. 2011 Jan;85(2):873–882.
   PubMed Web of Science ®Google Scholar
• Tang T, Bidon M, Jaimes JA, et al. Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antiviral Res. 2020 Jun;178:104792.
   PubMed Web of Science ®Google Scholar
• Padmanabhan P, Desikan R, Dixit NM. Targeting TMPRSS2 and cathepsin B/L together may be synergistic against SARS-CoV-2 infection. PLoS Comput Biol. 2020 Dec;16(12):e1008461.
   PubMed Web of Science ®Google Scholar
• Bestle D, Heindl MR, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance. 2020 Sep;3(9):e202000786.
   PubMed Web of Science ®Google Scholar
• Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol. 2020 May;92(5):491–494.
   PubMed Web of Science ®Google Scholar
• Cheng YW, Chao TL, Li CL, et al. Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects. Cell Rep. 2020 Oct 13;33(2):108254.
   PubMed Web of Science ®Google Scholar
• Wu C, Zheng M, Yang Y, et al. Furin: a potential therapeutic target for COVID-19. iScience. 2020 Oct 23;23(10):101642.
   PubMed Web of Science ®Google Scholar
• Chen RE, Zhang X, Case JB, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021 Apr;27(4):717–726.
   PubMed Web of Science ®Google Scholar